Gautham K Rao

Dr. Gautham K Rao

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2025 in Nature Medicine
Verified
Journal Article
Open access
PDF file
JLJuanita Lopez
Juanita Lopez
TPThomas Powles
Thomas Powles
FBFadi Braiteh
Fadi Braiteh
LSLillian L. Siu
Lillian L. Siu
PLPatricia LoRusso
Patricia LoRusso
DCD. Ross Camidge
D. Ross Camidge
Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from tumor-specific somatic mutation data obtained from tumor tissue of each individual patient to stimulate T cell responses against up to 20 neoantigens. This ongoing phase 1 study evaluated autogene cevumeran as monotherapy (n = 30) and in combination with atezolizumab (n = 183) in pretreated patients with advanced solid tumors. The primary objective was safety and tolerability; exploratory objectives included evaluation of pharmacokinetics, pharmacodynamics, preliminary antitumor activity and immunogenicity. Non-prespecified interim analysis showed that autogene cevumeran was well tolerated and elicited poly-epitopic neoantigen-specific responses, encompassing CD4+ and/or CD8+ T cells, in 71% of patients, most of them undetectable at baseline. Responses were detectable up to 23 months after treatment initiation. CD8+ T cells specific for several neoantigens constituted a median of 7.3% of circulating CD8+ T cells, reaching up to 23% in some patients. Autogene cevumeran-induced T cells were found within tumor lesions constituting up to 7.2% of tumor-infiltrating T cells. Clinical activity was observed, including one objective response in monotherapy dose escalation and in two patients with disease characteristics unfavorable for response to immunotherapy treated in combination with atezolizumab. These findings support the continued development of autogene cevumeran in earlier treatment lines. ClinicalTrials.gov registration: NCT03289962.

19 April 2025 in Cytotherapy
Verified
Journal Article
Open access
TWTakeshi Watanabe
Takeshi Watanabe
SSShin-La Shu
Shin-La Shu
ARAlberto del Rio-Espinola
Alberto del Rio-Espinola
JFJoana Rita Ferreira
Joana Rita Ferreira
KBKiyoko Bando
Kiyoko Bando
SYSatoshi Yasuda
Satoshi Yasuda
Human pluripotent stem cells (hPSCs) can differentiate into any cell of choice and hold significant promise in regenerative medicine and for treating diseases that currently lack adequate therapies. However, hPSCs are intrinsically tumorigenic and can form teratomas. Therefore, the presence of residual undifferentiated hPSCs must be rigorously assessed using sensitive methodologies to mitigate the potential tumorigenicity risks of hPSC-derived cell therapy products (CTPs). In this comprehensive review, we describe methods for detecting residual undifferentiated hPSCs and discuss the relative value of current in vitro assays versus conventional in vivo assays. We highlight that in vitro assays such as digital PCR detection of hPSC-specific RNA and the highly efficient culture assay, have superior detection sensitivity. Additionally, we outline important considerations for validating in vitro assays when applying them to assess each product. This article lays the groundwork for guiding internationally harmonized procedures for evaluating the potential teratoma formation risk of hPSC-derived CTPs and increasing confidence in the safety of these products.

15 May 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
IHIraj Hosseini
Iraj Hosseini
BFBrett Fleisher
Brett Fleisher
JGJennifer Alice Getz
Jennifer Alice Getz
JDJérémie Decalf
Jérémie Decalf
MKMandy Kwong
Mandy Kwong
SRSaroja Ramanujan
Saroja Ramanujan
FLT3L-Fc is a half-life extended, effectorless Fc-fusion of the native human FLT3-ligand. In cynomolgus monkeys, treatment with FLT3L-Fc leads to a complex pharmacokinetic/pharmacodynamic (PK/PD) relationship, with observed nonlinear PK and expansion of different immune cell types across different dose levels. A minimal physiologically based PK/PD model with expansion-enhanced target-mediated drug disposition (TMDD) was developed to integrate the molecule’s mechanism of action, as well as the complex preclinical and clinical PK/PD data, to support the preclinical-to-clinical translation of FLT3L-Fc. In addition to the preclinical PK data of FLT3L-Fc in cynomolgus monkeys, clinical PK and PD data from other FLT3-agonist molecules (GS-3583 and CDX-301) were used to inform the model and project the expansion profiles of conventional DC1s (cDC1s) and total DCs in peripheral blood. This work constitutes an essential part of our model-informed drug development (MIDD) strategy for clinical development of FLT3L-Fc by projecting PK/PD in healthy volunteers, determining the first-in-human (FIH) dose, and informing the efficacious dose in clinical settings. Model-generated results were incorporated in regulatory filings to support the rationale for the FIH dose selection.

22 February 2019 in Toxicological Sciences
Verified
Journal Article
Open access
PDF file
GRGautham K Rao
Gautham K Rao
RPRodney A Prell
Rodney A Prell
SLSteven T Laing
Steven T Laing
SBStefanie C M Burleson
Stefanie C M Burleson
ANAllen Nguyen
Allen Nguyen
WHWendy G Halpern
Wendy G Halpern
A theoretical safety concern proposed in the influenza literature is that therapeutic antiviral antibodies could have the potential for antibody-dependent enhancement (ADE) of infection and disease. ADE may occur when virus-specific antibodies at subtherapeutic, nonneutralizing concentrations facilitate virus uptake and, in some cases, enhance replication, which can lead to an exacerbation of virus-mediated disease. Alternatively, ADE may occur due to antibody-dependent complement activation exacerbating virus-mediated disease in the absence of increased replication. As a result of this theoretical safety concern, safety assessment of anti-influenza antibodies may include an in vivo evaluation of ADE of infection and/or disease. These studies were conducted to investigate the potential of MHAB5553A, a broadly specific, neutralizing therapeutic anti-influenza B antibody, to elicit ADE of infection and disease in mouse models of influenza B infection. In parallel studies, female DBA/2J mice were infected with either influenza B/Victoria/504/2000 or influenza B/Brisbane/60/2008 representing distinct lineages. Assessment of ADE was based on an integration of results from multiple endpoints, including infectious lung viral titers and genomes, body weight, mortality, lung weight, and histopathology. In these studies, the high dose of 15 mg/kg MHAB5553A resulted in substantial attenuation of influenza pneumonia, with more modest effects at 1.5 mg/kg; whereas MHAB5553A treatment at 0.15 or 0.015 mg/kg was generally comparable to vehicle-treated controls. Our results demonstrate that MHAB5553A across a broad range of doses did not enhance primary influenza B infection or disease in this model, and represent a nonclinical de-risking of the ADE potential with this antibody.

24 January 2024 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
KWKai Connie Wu
Kai Connie Wu
AAAdeyemi O. Adedeji
Adeyemi O. Adedeji
TZTanja S. Zabka
Tanja S. Zabka
IHIraj Hosseini
Iraj Hosseini
RKRadhika Kenkre
Radhika Kenkre
GRGautham K Rao
Gautham K Rao

21 December 2023 in Reproductive Toxicology
Verified
Journal Article
Closed access
GRGautham K Rao
Gautham K Rao
SSSara F. Santagostino
Sara F. Santagostino
LWLisa Wong
Lisa Wong
AIAyumi Inoue
Ayumi Inoue
AAAudrey Arjomandi
Audrey Arjomandi
WHWendy G. Halpern
Wendy G. Halpern